Prescott Group Capital Management L.L.C. Purchases New Position in LifeMD, Inc. $LFMD

Prescott Group Capital Management L.L.C. purchased a new stake in LifeMD, Inc. (NASDAQ:LFMD) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 687,328 shares of the company’s stock, valued at approximately $2,344,000.

Other large investors have also recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its holdings in shares of LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after purchasing an additional 2,452 shares during the period. Quarry LP purchased a new stake in shares of LifeMD in the third quarter valued at approximately $52,000. King Wealth Management Group purchased a new stake in shares of LifeMD in the third quarter valued at approximately $68,000. Legal & General Group Plc boosted its holdings in shares of LifeMD by 187.4% in the second quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock valued at $138,000 after purchasing an additional 6,614 shares during the period. Finally, Hudson Bay Capital Management LP purchased a new stake in shares of LifeMD in the second quarter valued at approximately $153,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Stock Down 0.9%

LifeMD stock opened at $4.26 on Thursday. The business has a fifty day moving average of $4.14 and a two-hundred day moving average of $3.82. The firm has a market cap of $206.03 million, a P/E ratio of 85.22 and a beta of 2.03. LifeMD, Inc. has a twelve month low of $2.56 and a twelve month high of $15.84.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.06). LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. The business had revenue of $50.16 million for the quarter, compared to analysts’ expectations of $48.84 million. Equities analysts expect that LifeMD, Inc. will post 0.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on LFMD shares. Loop Capital set a $10.00 price target on LifeMD in a report on Thursday, March 12th. Weiss Ratings upgraded LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a report on Thursday, May 7th. BTIG Research restated a “buy” rating and set a $10.00 target price on shares of LifeMD in a report on Monday, May 4th. Cantor Fitzgerald restated an “overweight” rating on shares of LifeMD in a report on Tuesday, March 10th. Finally, HC Wainwright upped their target price on LifeMD from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, LifeMD has a consensus rating of “Moderate Buy” and a consensus price target of $9.14.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.